Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xiao-Jian Zhou
Observed name:
Xiao‐Jian Zhou
Institution:
Atea Pharmaceuticals (United States)
Observed institution:
Atea Pharmaceuticals (United States)
ORCID:
0009-0009-7662-1616
Observed ORCID:
0009-0009-7662-1616
OpenAlex ID:
A5091120535
First-in-human trial evaluating safety and pharmacokinetics of AT-752, a novel nucleotide prodrug with pan-serotype activity against dengue virus
2024
·
Xiao-Jian Zhou
, Jason Lickliter
, et al.
·
Antimicrobial Agents and Chemotherapy
·
21
PDF
Bemnifosbuvir (BEM, AT-527), a novel nucleotide analogue inhibitor of the hepatitis C virus NS5B polymerase
2024
·
Xiao-Jian Zhou
, Steven S Good
, et al.
·
Expert Opinion on Investigational Drugs
·
11
Safety, Pharmacokinetics, and Activity of AT-752, a Novel Nucleotide Prodrug with Pan-Serotype Activity against Dengue Virus: A Phase 2, Randomized, Double-Blind Study
2025
·
Arantxa Horga
, Mauro M. Teixeira
, et al.
·
American Journal of Tropical Medicine and Hygiene
·
8
Human bronchopulmonary disposition and plasma pharmacokinetics of oral bemnifosbuvir (AT-527), an experimental guanosine nucleotide prodrug for COVID-19
2024
·
Xiao-Jian Zhou
, Arantxa Horga
, et al.
·
Journal of Antimicrobial Chemotherapy
·
5
WED-280 Pharmacokinetics of bemnifosbuvir in participants with renal impairment
2025
·
Xiao-Jian Zhou
, Gaetano Morelli
, et al.
·
Journal of Hepatology
·
1
Multiscale Modeling of an 8‐Week Combination Regimen of Bemnifosbuvir and Ruzasvir in Patients with Chronic Hepatitis C Virus Infection
2026
·
Carolin Zitzmann
, Ruy M. Ribeiro
, et al.
·
Clinical Pharmacology & Therapeutics
PDF
Show more works
View as search
Works count:
6
Citation count:
46
H-index:
4
I10-index:
2
Year
Topic
Type
